[Novo Nordisk sign on building, Danish pharmaceutical healthcare giant, production innovative drugs, obesity treatment Ozempic, pharmaceutical company innovation, Mainz, Germany June 15, 2024] Victor Golmer Close on the heels of a major rebranding exercise, Novo Nordisk's (NVO [https://seekingalpha.com/symbol/NVO]) CEO Mike Doustdar on Tuesday urged his employees to be more consumer-focused as the weight-loss drugmaker attempts to regain market share lost to rival Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]). "We would like to become a better and a bigger company. A company that does more for many more, both patients and consumers," s [https://www.reuters.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.
